There are currently 634 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Heart Failure Precision Medicine Study
NCT04196842
Recruiting
The study aims to test the hypothesis that multi-omics studies can identify Heart Failure profiles at risk of adverse outcomes and evaluate a telemonitoring intervention in the optimization of guideline-directed medical therapy.
Gender:
All
Ages:
21 years and above
Trial Updated:
02/01/2022
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Heart Failure
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Recruiting
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Sacramento, California
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Centre of Excellence in Diabetes and Endocrinology, Sacramento, California
Conditions: Diabetes
Register for Updates
Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)
NCT04867512
Recruiting
The purpose of this study is to assess how an oral botanical blend alters the gut microbiome and the skin biophysical properties in people with SIBO.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/29/2021
Locations: Integrative Skin Science and Research, Sacramento, California
Conditions: Small Intestinal Bacterial Overgrowth (SIBO)
Register for Updates
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
NCT03250338
Recruiting
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: City of Hope National Medical Center, Sacramento, California +1 locations
Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Register for Updates
The Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis
NCT04338607
Recruiting
The purpose of this study is to determine the clinical efficacy of a novel dynamic sustained compression intramedullary nail for subtalar (talocalcaneal) arthrodesis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2021
Locations: University of California, Davis Medical Center, Sacramento, California
Conditions: Foot Arthritis
Register for Updates
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
NCT03258931
Recruiting
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treat... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2020
Locations: US Davis Health, Sacramento, California
Conditions: Newly Diagnosed FLT3 Mutated AML
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
All
Ages:
All
Trial Updated:
04/01/2020
Locations: UC Davis Health, Sacramento, California
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
NCT02803957
Recruiting
The objective of this trial is to assess the safety and effectiveness of the study device in subjects with degenerative mitral valve disease receiving a mitral valve repair without cardiopulmonary bypass (treatment group) when compared to subjects receiving mitral valve repair using standard surgical techniques with cardiopulmonary bypass (control group).
Gender:
All
Ages:
21 years and above
Trial Updated:
12/04/2019
Locations: Mercy General Hospital, Sacramento, California
Conditions: Mitral Valve Insufficiency
Register for Updates
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
NCT02137668
Recruiting
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Gender:
All
Ages:
Between 2 weeks and 40 years
Trial Updated:
11/10/2016
Locations: Sacramento Pediatric Gastroenterology, Sacramento, California
Conditions: Primary Sclerosing Cholangitis, Biliary Atresia
Register for Updates